Kymera Investor Day Presentation Deck

Full and Durable Regressions Across Multiple in vivo Preclinical Tumor Models Mice bearing STAT3- dependent ALK+ ALCL SU- DHL-1 or SUP-M2 tumor xenografts dosed with STAT3 degrader Dose- and degradation dependent tumor growth inhibition observed with once- a-week dosing 10 mg/kg sufficient to drive full tumor regression in SU- DHL- 1 that was durable for multiple weeks after the last dose (on day 14) KYMERA ©2021 KYMERA THERAPEUTICS, INC. Tumor Volume (mm³) Mean, ± SEM 3000 2000 1000 SU-DHL-1 Weekly Dosing - - Vehicle KT-333, 5 mg/kg QW KT-333, 10 mg/kg QW KT-333, 15 mg/kg QW KT-333, 45 mg/kg QW 01 10 5 15 Days (Post-randomization) 20 KYMERA R&D DAY - December 16th, 2021 25 Tumor Volume (mm³) Mean, ± SEM 3000 2000 1000 SUP-M2 Weekly Dosing Vehicle KT-333, 10 mg/kg QW KT-333,20 mg/kg QW KT-333, 30 mg/kg QW 20 40 Days (Post-randomization) 60 PAGE 62

View entire presentation